BARCELONE, Espagne–(BUSINESS WIRE)–Yeux rouges et irrités, démangeaisons et brûlure, ainsi que la sensation d’avoir un corps étranger sous la paupière sont les symptômes les plus courants du syndrome de l’œil sec, un problème de plus en plus commun lié à des facteurs environnementaux, à des comportements et à des modes de vie et qui entraîne une diminution de la lubrification oculaire. Le syndrome de l’œil sec est souvent sous-estimé, mais il peut avoir des répercussions significatives sur la
BARCELONA, Spanien–(BUSINESS WIRE)–Rötungen und Reizungen sowie Jucken und Brennen des Auges und das Gefühl, einen Fremdkörper unter dem Augenlid zu haben, sind die häufigsten Symptome des Trockenen Auges, ein immer häufiger auftretendes Problem, das mit Umwelt-, Verhaltens- und Lebensstilfaktoren verbunden ist, die zu einer verminderten Augenschmierung führen. Das Trockene Auge wird häufig unterschätzt, kann jedoch erhebliche Auswirkungen auf das Sehvermögen der Patienten haben, insbesondere
BARCELONA, Spain–(BUSINESS WIRE)–Eye redness and irritation, itchiness and burning of the eye and the sensation of having a foreign body under the eyelid are the most common symptoms of Dry Eye disease, an increasingly common problem associated with environmental, behavioural and lifestyle factors which lead to decreased ocular lubrication. Dry Eye disease is frequently underestimated but can have significant repercussions on patients’ eyesight, especially in its moderate and severe forms. Th
BARCELLONA, Spagna–(BUSINESS WIRE)–Arrossamento e irritazione agli occhi, prurito e bruciore, vista annebbiata, sensazione di un corpo estraneo nella palpebra. Sono solo alcuni dei più comuni sintomi che caratterizzano la sindrome dell’occhio secco, una condizione sempre più diffusa a causa di fattori ambientali ma anche per comportamenti e stili di vita che portano a trascurare l’importanza di una corretta lubrificazione oculare. La patologia, spesso sottovalutata ma che può avere ripercussi
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics has been awarded the honor of iPSC industry influencer by BioInformant, a leading research firm serving the stem cell sector. Dr. Lanza was honored both for his specific involvement in early-stage, pioneering research in the area of induced Pluripotent Stem Cells, or “iPSCs”, as we
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO invited to speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual symposium in Scottsdale September 21-23
BARCELONA, España–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD®) ha anunciado en el Ophthalmology Futures European Forum 2015 que su fuente braquiterápica y de radionúclidos SMD Sr90-1 ha recibido la autorización 510(k) de la Administración de Alimentos y Medicamentos de EE. UU. La SMD Sr90-1 RBS está indicada para la braquiterapia episcleral de tumores y crecimientos benignos y diseñada para usarse con sistemas de aplicación de braquiterapia manuales. Laurence Marsteller, CEO de Sa
BARCELONA, Spanje–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD ®) heeft op het Ophthalmology Futures European Forum 2015 bekendgemaakt dat zijn SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) een 510(k)-autorisatie heeft gekregen van de Amerikaanse Food and Drug Administration (FDA). De SMD Sr90-1 RBS is bedoeld voor inwendige episclerale bestraling van tumoren of goedaardige groei. Het dient te worden toegepast in een handmatig bestuurbaar systeem voor inwendige bestraling. Laur
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that its Board of Directors has appointed Steve Davis as President and Chief Executive Officer. Mr. Davis has been serving as ACADIA’s Interim Chief Executive Officer since March 2015. Mr. Davis has also been appointed to the ACADIA Board of
HONOLULU–(BUSINESS WIRE)–Bruker (NASDAQ: BRKR) today introduced four important new preclinical imaging systems at the World Molecular Imaging Congress 2015 (WMIC, www.wmis.org) in Honolulu, Hawaii. The novel products launched at WMIC each deliver improved performance and convenience for routine imaging, and open new horizons for advanced translational research, while Bruker’s platform philosophy facilitates multimodal imaging projects. Researchers will gain a more complete picture and deeper
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. NUPLAZID is an SSIA (selective sero
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel topical non-antibiotic antimicrobial products for the global eye care market, announces that President and CEO Ron Najafi, Ph.D., will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the St. Regis Hotel
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Announces New Date for Special Stockholder Meeting
BARCELONE, Espagne–(BUSINESS WIRE)–À l’occasion de l’Ophthalmology Futures European Forum 2015, Salutaris Medical Devices (SalutarisMD®) a annoncé que sa source de curiethérapie à radionucléides (SCR) SMD Sr90-1 a obtenu l’homologation 510(k) de l’Agence américaine des produits alimentaires et des médicaments (la « FDA »). La SCR SMD Sr90-1 est indiquée pour la curiethérapie épisclérale des tumeurs et des croissances bénignes, elle est prévue pour une utilisation dans un système applicateur d
BARCELONA, Spanien–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD®) gab auf dem Ophthalmology Futures European Forum 2015 bekannt, dass seine SMD Sr90-1-Radionuklid-Brachytherapie-Strahlenquelle (RBS) die Zulassung der US-Gesundheitsbehörde nach dem 510(k)-Verfahren erhalten hat. Die SMD Sr90-1 RBS ist bei der episkleralen Brachytherapie von Tumoren und gutartigen Wucherungen angezeigt und für die Verwendung in einem manuellen Brachytherapie-Applikator-System bestimmt. Dr. Laurence Ma
BARCELLONA, Spagna–(BUSINESS WIRE)–Nel corso dell’Ophthalmology Futures European Forum 2015, Salutaris Medical Devices (SalutarisMD®) ha annunciato che il suo prodotto SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) ha ricevuto l’approvazione 510(k) dalla Food and Drug Administration (FDA) degli Stati Uniti. SMD Sr90-1 RBS è indicato per la brachiterapia episclerale dei tumori e delle escrescenze benigne e va utilizzato nell’ambito di un sistema con applicatore manuale per brachiterapia. “
BARCELONA, Spain–(BUSINESS WIRE)–At Ophthalmology Futures European Forum, Salutaris Medical Devices announces 510(k) clearance for device indicated for episcleral brachytherapy.
DUBLIN, Calif.–(BUSINESS WIRE)–ZEISS sets the pace in OCT innovation with the FDA 510(k) clearance of AngioPlex OCT Angiography, the first next generation vascular imaging technology approved in the U.S.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI), part of the National Institutes of Health (NIH), to fund Investigational New Drug (IND)-enabling preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as r
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven announces promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to SVP, Finance. Mr. McCabe is also Principal Financial and Accounting Officer.